- Home
- BB vs RARE Comparison
BB vs RARE Comparison
Compare BB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BB
- RARE
- Stock Information
- Founded
- BB 1984
- RARE 2010
- Country
- BB Canada
- RARE United States
- Employees
- BB N/A
- RARE N/A
- Industry
- BB
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- BB
- RARE Health Care
- Exchange
- BB Nasdaq
- RARE Nasdaq
- Market Cap
- BB 2.2B
- RARE 2.6B
- IPO Year
- BB 1997
- RARE 2014
- Fundamental
- Price
- BB $3.88
- RARE $31.82
- Analyst Decision
- BB Buy
- RARE Strong Buy
- Analyst Count
- BB 6
- RARE 14
- Target Price
- BB $4.64
- RARE $86.64
- AVG Volume (30 Days)
- BB 5.9M
- RARE 1.3M
- Earning Date
- BB 09-25-2025
- RARE 11-04-2025
- Dividend Yield
- BB N/A
- RARE N/A
- EPS Growth
- BB N/A
- RARE N/A
- EPS
- BB N/A
- RARE N/A
- Revenue
- BB $533,200,000.00
- RARE $610,159,000.00
- Revenue This Year
- BB $2.17
- RARE $19.72
- Revenue Next Year
- BB $7.03
- RARE $23.29
- P/E Ratio
- BB N/A
- RARE N/A
- Revenue Growth
- BB 4.65
- RARE 26.77
- 52 Week Low
- BB $2.22
- RARE $25.81
- 52 Week High
- BB $6.24
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- BB 55.84
- RARE 61.88
- Support Level
- BB $3.70
- RARE $31.03
- Resistance Level
- BB $3.95
- RARE $32.58
- Average True Range (ATR)
- BB 0.10
- RARE 0.88
- MACD
- BB 0.03
- RARE 0.38
- Stochastic Oscillator
- BB 80.77
- RARE 79.62
About BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.